WO2008043461A3 - Inhibition der pde2a - Google Patents
Inhibition der pde2a Download PDFInfo
- Publication number
- WO2008043461A3 WO2008043461A3 PCT/EP2007/008561 EP2007008561W WO2008043461A3 WO 2008043461 A3 WO2008043461 A3 WO 2008043461A3 EP 2007008561 W EP2007008561 W EP 2007008561W WO 2008043461 A3 WO2008043461 A3 WO 2008043461A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prophylaxis
- diseases
- pde2a
- inhibition
- atherosclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07818641A EP2124955A2 (de) | 2006-10-14 | 2007-10-02 | Inhibition der pde2a |
US12/444,708 US20100035882A1 (en) | 2006-10-14 | 2007-10-02 | Inhibition of pde2a |
CA002666355A CA2666355A1 (en) | 2006-10-14 | 2007-10-02 | Inhibition of pde2a |
JP2009531740A JP2010506561A (ja) | 2006-10-14 | 2007-10-02 | Pde2aの阻害 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006048693.5 | 2006-10-14 | ||
DE102006048693A DE102006048693A1 (de) | 2006-10-14 | 2006-10-14 | Inhibition der PDE2A |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008043461A2 WO2008043461A2 (de) | 2008-04-17 |
WO2008043461A3 true WO2008043461A3 (de) | 2008-08-28 |
Family
ID=39184962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/008561 WO2008043461A2 (de) | 2006-10-14 | 2007-10-02 | Inhibition der pde2a |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100035882A1 (de) |
EP (1) | EP2124955A2 (de) |
JP (1) | JP2010506561A (de) |
CA (1) | CA2666355A1 (de) |
DE (1) | DE102006048693A1 (de) |
WO (1) | WO2008043461A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
MY173949A (en) | 2012-04-25 | 2020-02-28 | Takeda Pharmaceuticals Co | Nitrogenated heterocyclic compound |
EP2873669A4 (de) | 2012-07-13 | 2015-11-25 | Takeda Pharmaceutical | Heterocyclische verbindung |
US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
WO2014142255A1 (ja) | 2013-03-14 | 2014-09-18 | 武田薬品工業株式会社 | 複素環化合物 |
JP6411342B2 (ja) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | アミド化合物 |
US10053468B2 (en) | 2013-07-03 | 2018-08-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9815796B2 (en) | 2013-12-23 | 2017-11-14 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as PDE2 inhibitors |
JP2017114764A (ja) * | 2014-04-25 | 2017-06-29 | 武田薬品工業株式会社 | 片頭痛治療剤 |
EP3156405A1 (de) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclische etherderivate von pyrazolo[1,5-a]pyrimidin-3-carboxamid |
EP3713572A1 (de) | 2017-11-23 | 2020-09-30 | Oslo University Hospital HF | Behandlung von tachykardie |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4278673A (en) * | 1977-03-25 | 1981-07-14 | Allen & Hanburys Limited | Pharmacologically active compounds |
WO2004044234A1 (en) * | 2002-11-13 | 2004-05-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) |
US20060168668A1 (en) * | 2003-04-04 | 2006-07-27 | Memory Pharmaceuticals Corporation | Phosphodiesterase 2a and methods of use |
WO2007100618A2 (en) * | 2006-02-23 | 2007-09-07 | Atto Bioscience | Novel cell-based phosphodiesterase assays |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0113343D0 (en) * | 2001-06-01 | 2001-07-25 | Bayer Ag | Novel Heterocycles 2 |
-
2006
- 2006-10-14 DE DE102006048693A patent/DE102006048693A1/de not_active Withdrawn
-
2007
- 2007-10-02 WO PCT/EP2007/008561 patent/WO2008043461A2/de active Application Filing
- 2007-10-02 CA CA002666355A patent/CA2666355A1/en not_active Abandoned
- 2007-10-02 US US12/444,708 patent/US20100035882A1/en not_active Abandoned
- 2007-10-02 EP EP07818641A patent/EP2124955A2/de not_active Withdrawn
- 2007-10-02 JP JP2009531740A patent/JP2010506561A/ja not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4278673A (en) * | 1977-03-25 | 1981-07-14 | Allen & Hanburys Limited | Pharmacologically active compounds |
WO2004044234A1 (en) * | 2002-11-13 | 2004-05-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) |
US20060168668A1 (en) * | 2003-04-04 | 2006-07-27 | Memory Pharmaceuticals Corporation | Phosphodiesterase 2a and methods of use |
WO2007100618A2 (en) * | 2006-02-23 | 2007-09-07 | Atto Bioscience | Novel cell-based phosphodiesterase assays |
Non-Patent Citations (2)
Title |
---|
CASTRO L R V ET AL: "Cyclic guanosine monophosphate compartimentation in rat cardiac myocytes", CIRCULATION, vol. 113, 1 May 2006 (2006-05-01), pages 2221 - 2228, XP002477670 * |
IFFLAND A ET AL: "Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system", BIOCHEMISTRY, vol. 44, 2005, pages 8312 - 8325, XP002477671 * |
Also Published As
Publication number | Publication date |
---|---|
JP2010506561A (ja) | 2010-03-04 |
EP2124955A2 (de) | 2009-12-02 |
WO2008043461A2 (de) | 2008-04-17 |
DE102006048693A1 (de) | 2008-04-17 |
US20100035882A1 (en) | 2010-02-11 |
CA2666355A1 (en) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008043461A3 (de) | Inhibition der pde2a | |
WO2010042163A3 (en) | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders | |
PL3026044T3 (pl) | Inhibitory prolilo-hydroksylazy i sposoby ich użycia | |
EA201070339A1 (ru) | Активаторы растворимой гуанилатциклазы | |
WO2009067600A3 (en) | Biaryl pde4 inhibitors for treating inflammation | |
EP2213668A3 (de) | Imidazole als Aldosterone Synthase Inhibitoren | |
WO2006056889A3 (en) | Method and composition for enhancing anti-angiogenic therapy | |
MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
WO2007117982A3 (en) | Organic compounds | |
UY28958A1 (es) | Nuevos derivados de piridazin-3(2h)-ona | |
CY1112215T1 (el) | Πιμοβενδανη που θα χρησιμοποιηθει για τη μειωση του μεγεθους της καρδιας σε θηλαστικα που υποφερουν απο καρδιακη ανεπαρκεια | |
EA201171361A1 (ru) | Ингибиторы внешнего медуллярного калиевого канала почек | |
WO2007041368A3 (en) | Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection | |
WO2009036175A3 (en) | F1f0-atpase inhibitors and related methods | |
EP2674417A3 (de) | Biaryl-PDE4-Inhibitoren zur Behandlung von Entzündungen | |
WO2006034402A3 (en) | Compounds for inflammation and immune-related uses | |
WO2004020410A3 (en) | Dihydropyridinone derivatives as hne inhibitors | |
WO2008061720A3 (en) | Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders | |
NO20070827L (no) | Farmasoytiske formuleringer inneholdende en blodplateaggregregeringsinnhibitor og et fibrat. | |
WO2007019153A3 (en) | Methods for treating hypertension | |
WO2010030891A3 (en) | Aryl guanidine f1f0-atpase inhibitors and related methods | |
IL186374A (en) | Combined use of prostaglandin compound and ppi for the manufacture of pharmacological compounds for the treatment of gastrointestinal disorders and pharmaceutical compounds containing them | |
WO2007014033A3 (en) | Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure | |
WO2009074969A3 (en) | Spingosine-1-phosphate, analogues and antagonists for use as medicaments | |
WO2011149288A3 (ko) | 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2007818641 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12444708 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2666355 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009531740 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07818641 Country of ref document: EP Kind code of ref document: A2 |